Warning: The NCBI web site requires JavaScript to function. more...
Case report: a case of intractable Meniere's disease treated with autogenic training.
Goto F, Nakai K, Kunihiro T, Ogawa K.
Biopsychosoc Med. 2008 Jan 25;2:3.
Related citations
Long-term hearing outcome in patients receiving intratympanic gentamicin for Ménière's disease.
Wu IC, Minor LB.
Laryngoscope. 2003 May;113(5):815-20.
Intratympanic gentamicin for intractable Meniere's disease.
Perez N, Martín E, García-Tapia R.
Laryngoscope. 2003 Mar;113(3):456-64.
[Intratympanic gentamicin treatment for intractable Menière's disease].
Gilony D, Wolf M, Kronenberg J.
Harefuah. 2004 Jan;143(1):4-7, 88. Hebrew.
Intratympanic gentamicin for control of vertigo in Meniere's disease: vestibular signs that specify completion of therapy.
Minor LB.
Am J Otol. 1999 Mar;20(2):209-19.
Efficacy of increased gentamicin concentration for intratympanic injection therapy in Ménière's disease.
Abou-Halawa AS, Poe DS.
Otol Neurotol. 2002 Jul;23(4):494-502; discussion 502-3.
Initial symptoms and retrospective evaluation of prognosis in Menière's disease.
Tokumasu K, Fujino A, Naganuma H, Hoshino I, Arai M.
Acta Otolaryngol Suppl. 1996;524:43-9.
Hearing results following intratympanic gentamicin perfusion for Ménière's disease.
Kyrodimos E, Aidonis I, Sismanis A.
J Laryngol Otol. 2009 Apr;123(4):379-82. Epub 2008 Oct 28.
Long-term effects of the Meniett device in Ménière's disease: the Western Australian experience.
Rajan GP, Din S, Atlas MD.
J Laryngol Otol. 2005 May;119(5):391-5.
Intratympanic therapy for Ménière's disease. High-concentration gentamicin with round-window protection.
Quaranta A, Aloisi A, De Benedittis G, Scaringi A.
Ann N Y Acad Sci. 1999 Nov 28;884:410-24.
Intratympanic dexamethasone and hyaluronic acid in patients with low-frequency and Ménière's-associated sudden sensorineural hearing loss.
Selivanova OA, Gouveris H, Victor A, Amedee RG, Mann W.
Otol Neurotol. 2005 Sep;26(5):890-5.
Intratympanic gentamicin injection for the treatment of Meniere's disease.
Youssef TF, Poe DS.
Am J Otol. 1998 Jul;19(4):435-42.
Hearing loss after intratympanic gentamicin therapy for unilateral Ménière's Disease.
Martin E, Perez N.
Otol Neurotol. 2003 Sep;24(5):800-6.
Factors relating to the vertigo control and hearing changes following intratympanic gentamicin for intractable Ménière's disease.
Horii A, Saika T, Uno A, Nishiike S, Mitani K, Nishimura M, Kitahara T, Fukushima M, Nakagawa A, Masumura C, Sasaki T, Kizawa K, Kubo T.
Otol Neurotol. 2006 Sep;27(6):896-900.
High-dose intratympanic gentamicin instillations for treatment of Meniere's disease: long-term results.
Hsieh LC, Lin HC, Tsai HT, Ko YC, Shu MT, Lin LH.
Acta Otolaryngol. 2009 Dec;129(12):1420-4.
[Intratympanic treatment in Meniere's disease: the effect of gentamicin and dexamethasone on vertigo control and hearing].
Akkuzu B, Ozgirgin N, Ozlüoğlu LN.
Kulak Burun Bogaz Ihtis Derg. 2006;16(5):193-9. Turkish.
[Follow-up assessment of intratympanic gentamicin therapy and Saccotomia in Menière's Disease].
Tauber S, Jäger L, Issing WJ.
Laryngorhinootologie. 2002 May;81(5):335-41. German.
[Psychiatric manifestations of lupus erythematosus systemic and Sjogren's syndrome].
Ampélas JF, Wattiaux MJ, Van Amerongen AP.
Encephale. 2001 Nov-Dec;27(6):588-99. French.
[Long-term results of transtympanic gentamicin treatment in Meniere's disease].
Pierchała K, Krzeska-Malinowska I, Kowalska M, Bartoszewicz R, Niemczyk K.
Otolaryngol Pol. 2005;59(3):409-13. Polish.
Phobic postural vertigo treated with autogenic training: a case report.
Cases J. 2008 Sep 30;1(1):189.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on